Biofrontera (BFRI) Notes Payables (2023 - 2024)

Biofrontera (BFRI) recorded quarterly Notes Payables of $296000.0 in Q2 2024, down 87.43% quarter-over-quarter from $2.4 million in Q1 2024.

Biofrontera (BFRI) Notes Payables (2023 - 2024) Analysis & Trends

Biofrontera's Notes Payables history runs 2 years deep, the most recent figure standing at $296000.0 for Q2 2024.

In Q2 2024, Notes Payables changed N/A year-over-year to $296000.0; the TTM figure through Jun 2024 stood at $296000.0 (changed N/A YoY), while the FY2023 annual figure was $3.9 million, changed N/A from the prior year.
Notes Payables was $296000.0 for Q2 2024 at Biofrontera, down from $2.4 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $3.9 million in Q4 2023 to a low of $296000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Biofrontera	8.65 Mn	2.24 Mn	14.09 Mn

Download Data